title: Long-term care of pediatric renal transplant patients: from bench to bedside.
abstract: In this review, we discuss current and future issues in the management of pediatric renal transplant recipients, including the optimization of long-term graft function and the minimization of complications caused by immunosuppression. Long-term management involves not only the monitoring of graft function but also the identification of patients at risk for the development of complications. The identification of patients with immunoreactive or immunoregulatory responses can be performed molecular monitoring of the immune response. Also, the use of frequent surveillance kidney biopsies, surrogate markers of chronic rejection, and glomerular filtration rate will be a part of future management. Identifying high-risk patients enables the physician to optimize immunosuppression to limit acute rejection. Short-and long-term management of pediatric transplant patients also includes adequate monitoring of growth and the monitoring for post-transplant lymphoproliferative disease. Ongoing clinical trials are underway that focus on these novel approaches in caring for pediatric transplant recipients.
authors: Division of Nephrology, Department of Medicine, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
authors: Dmitry
authors: D
authors: Samsonov
authors: David M
authors: DM
authors: Briscoe
mesh_terms: D065095:Calcineurin Inhibitors; D002648:Child; D004359:Drug Therapy, Combination; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006084:Graft Rejection / Q000188:drug therapy / Q000209:etiology*; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000534:rehabilitation*; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015375:Receptors, Interleukin-2 / Q000627:therapeutic use; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D019382:Human Growth Hormone; D009173:Mycophenolic Acid; D020123:Sirolimus